Inhibikase Therapeutics, Inc. (IKT)
2.43
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 12:39
Inhibikase Therapeutics Total Assets (Quarterly) : 163.59M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 163.59M |
| March 31, 2026 | 173.33M |
| December 31, 2025 | 181.20M |
| September 30, 2025 | 79.59M |
| June 30, 2025 | 88.85M |
| March 31, 2025 | 94.28M |
| December 31, 2024 | 98.60M |
| September 30, 2024 | 4.377M |
| June 30, 2024 | 8.827M |
| March 31, 2024 | 11.07M |
| December 31, 2023 | 14.51M |
| September 30, 2023 | 17.88M |
| June 30, 2023 | 22.35M |
| March 31, 2023 | 28.16M |
| December 31, 2022 | 24.94M |
| September 30, 2022 | 28.58M |
| June 30, 2022 | 33.99M |
| March 31, 2022 | 38.39M |
| Date | Value |
|---|---|
| December 31, 2021 | 42.47M |
| September 30, 2021 | 45.87M |
| June 30, 2021 | 49.22M |
| March 31, 2021 | 11.87M |
| December 31, 2020 | 14.78M |
| September 30, 2020 | |
| June 30, 2020 | 0.3666M |
| March 31, 2020 | 0.0377M |
| December 31, 2019 | 0.0383M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 2.846M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | 0.3005M |
| December 31, 2017 | 0.2852M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
| Vericel Corp. | 502.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 10.26M |
| Shareholders Equity (Quarterly) | 153.33M |
| Current Ratio | 15.82 |
| Net Debt Paydown Yield | 0.01% |